Abstract Details

Title Serum Lipids and Cerebral Amyloidosis in Persons with High Vascular Risk

Topic Aging and Dementia

Presentation(s) S04 - (-)

Poster/Presentation
Number 003

Objective

Background Cholesterol is involved in the generation, transport, and deposition of beta amyloid (A?), a key molecular marker of Alzheimer's disease (AD). There is limited evidence that lipid profiles that elevate cardiac risk are associated with lower CSF A? and memory dysfunction.

Design/Methods Participants were 66 persons from the Aging Brain study, recruited for elevated vascular risk; 31 had Clinical Dementia Rating Scale (CDR) scores of 0 (normal), 32 scored 0.5, and 3 scored 1 (demented). Mean age was 78. Of the 62 cases with apoE genotyping 18 were E4+. Fasting HDL, LDL cholesterol, and triglycerides were assayed. Apolipoprotein A and apolipoprotein B, which are, respectively, anti-atherogenic and atherogenic factors were quantified. Cerebral A? was measured using PIB PET; regional DVRs were calculated using a cerebellar reference region and overall PIB retention was quantified by a global PIB index, the average of cortical regions vulnerable to amyloid deposition. Using an index threshold derived from young healthy controls 31 cases were defined as having elevated cerebral A?.

Results In a multiple regression covarying age and sex, the HDL/LDL ratio had a significant effect on PIB index. A lower ratio was associated with higher PIB (p = .01). Adding E4 status to the model left the strength of association essentially unchanged (p = .007); E4 had an independent effect on PIB (p = .03). In analogous models, the apoA/apoB ratio had a significant inverse relationship with PIB index (p = .015) that remained significant covarying E4 (p = .03). Adding CDR to the models above did not substantially alter the results. No clear effects emerged for triglycerides.

Conclusions Atherogenic cholesterol ratios were associated with elevated cerebral A? in this non-demented sample of persons with elevated vascular risk.

Authors/Disclosures
Bruce R. Reed, PhD (UC Davis Alzheimer's Disease Ctr) PRESENTER	No disclosure on file
	No disclosure on file
Charles S. DeCarli, MD, FAAN (UC Davis Health - Dept of NeurologyAlzheimer's Disease Research Center)	Dr. DeCarli has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. The institution of Dr. DeCarli has received research support from NIH.
Helena C. Chui, MD (University of Southern California)	The institution of Dr. Chui has received research support from National Institute on Aging .
William Jagust, MD (Helen Wills Neuroscience Institute)	No disclosure on file
Joyce A. Cramer (Yale University School of Medicine)	No disclosure on file

��ɫ��

��ɫ��